Liver support systems for adults with acute liver failure.
Martí-Carvajal AJ et al., 2026 · 11 studies included
Summary
Eleven randomized trials, 681 participants, evaluating artificial/bioartificial systems plus standard care in ALF.
Conclusion
Effects on 28-day mortality (RR 0.83, 95% CI 0.58–1.19), transplantation and serious adverse events were very uncertain. Do not promise survival benefit from liver-support devices or delay transplantation assessment. This review is not a substitute for intervention-specific plasma-exchange evidence or ASFA indications.